OncoBREAST Dx - Order Form

Biochemistry

General:  
- Creatinine  
- GGT  
- CA 15.3 (Serum Tumor Markers:)
- NGAL  
- Total Bilirubin  
- CEA  
- NSE  
- ALAT  
- EGFR  
- 8-OHdG

Anamnesis

Personal Data
Age (years):

Comorbidities
- Atherosclerosis: Yes, No, Unknown
- Chronic Liver Disease: Yes, No, Unknown
- Diabetes Mellitus 1 or 2: Yes, No, Unknown
- Jaundice: Yes, No, Unknown
- Renal Failure: Yes, No, Unknown

Lifestyle
Smoking: Never, Currently, Past

Order Information
Ordered by: [ ] Signature: [ ]
Order Date: [ ]

Disclaimer

According to Annex VII of Medical Device Directive 93/42/EEC, Class I, Rule 12, OncoBREAST Dx is a non-invasive blood and urine test useful to suggest a possible diagnosis in women with suspected malignancy in the breast, reduce inappropriate diagnostic tests, days of hospitalization, as well as morbidity. It is specially designed for women with a suspicious lump found in the breast, as a complementary method in radiological testing for high-risk women or those with a level of BI-RADS 3 and 4A (image findings suspicious of Breast Cancer that should be biopsied to verify malignancy), as well as women with family history of Breast Cancer.

OncoBREAST Dx is based in a panel consisting of 6 serum Tumor Markers (CA 15.3, CEA, EGFR, NGAL, NSE and 8-OHdG), as well as clinical data to obtain the best performance (Sensitivity of 82.3% and Specificity of 85.7%), by reducing the number of false positives generated by benign comorbidities and other well-known causes.